How did you decide to participate in the Biomapas Academy?
The first thing that caught my attention was the Biomapas Academy poster hanging on my university’s bulletin board. Shortly afterwards, the faculty management shared Biomapas’ invitation to register for the first Biomapas Academy. I wanted to learn more about this company, so I decided to take my chances and apply to the Academy. I was thrilled when I received a call with the happy news that I had successfully passed the selection process and was invited to attend the Academy.
What was your experience during the three months?
I listened to many interesting lectures, during which we got to know the company and its areas of activity. We listened to lectures on clinical trials and their organization, pharmacovigilance, regulatory affairs, bioethics, drug registration, and more. I believe that the knowledge gained at the Academy is valuable and helpful for all participants of the Academy and their future careers.
What did the future hold for you after the Academy?
I mainly was interested in pharmacovigilance, so we agreed on an internship in this department during the summer. Interesting fact: the first Biomapas poster I saw was about pharmacovigilance! And the best thing is that after the internship, I was able to join and become a part of this great team. I am happy to be here and to learn from real professionals in this field.
What would you say to the future participants?
I want to encourage everyone who is thinking about participating in the Biomapas Academy. Being at the Academy is exciting and worthwhile. By joining the Academy, you will broaden your horizons, learn from global professionals, improve your life sciences knowledge, and gain valuable experience. I wish good luck to all participants. See you soon at Biomapas!
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
All you need to know about the FDA’s Draft Guidance on Diversity Action Plans
The U.S. Food and Drug Administration’s (FDA) draft guidance on Diversity Action Plans (DAPs) is a significant step towards addressing the underrepresentation of diverse populations in clinical research. Released in June 2024, this guidance aligns with broader efforts...
Biomapas Announces Strategic Partnership to Drive Future Growth
Carbyne Equity Partners has signed to acquire majority ownership in UAB Biomapas.
Diversity in Clinical Trials: Significance & Challenges
Diversity in Clinical Trials: Significance & Challenges By Jan Filakovsky, CEO of BiomapasDiversity in clinical trials is crucial in ensuring that research findings are broadly applicable, and in avoiding treatments that are ineffective or even harmful to...
Partnering for Success: Specialised Rescue Studies in Georgia
Discover the benefits of conducting clinical trials in Georgia through this case study of three pharmaceutical companies.
Unlocking Success: The FSP Advantage in Clinical Research
The Functional Service Provider (FSP) models in clinical research are becoming increasingly appealing to the pharmaceutical and biotechnology sectors, offering flexible and scalable solutions to outsource specific functions . Currently pharmaceutical and...
Literature monitoring of Pharmacovigilance in realities of war in Ukraine
The need for continuous monitoring of drug safety in a country at war, and the ability to adapt to the circumstances for ensuring the safety of patients, is critical.
Bridging Gaps in Clinical Trials: Enhanced Access & Embracing Diversity
Explore the crucial role of diversity and accessibility in clinical research in this insightful article.
Pharmacovigilance & CSV: System Upgrades
Explore the intersection of Pharmacovigilance & CSV during system upgrades. Ensure drug safety while optimizing computer system validation.
Adaptive Clinical Trials
What are Adaptive Clinical Trials? And how can we leverage their distinguished ability to evolve to improve clinical designs?
CSV & Risk Management in Pharmacovigilance
CSV & Risk Management Pharmacovigilance stands as a guardian in drug development and monitoring, ensuring that medicines remain safe and effective throughout their lifecycle. But behind this sentinel lies a complex web of systems, processes, and regulations, each...
